We present long-term overall survival data for patients with malignant pleural mesothelioma enrolled in the KEYNOTE-028 study
2017
OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028
Key concepts
Scholarcy highlights
- Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and limited treatment options after progression on platinumcontaining chemotherapy
- OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028
- Schellens5 1University of Pennsylvania, Philadelphia/PA/United States of America, 2Drug Development Unit, Institute of Cancer Research, Sutton/ United Kingdom, 3Istituto Clinico Humanitas, Milan/Italy, 4Merck & Co., Inc., Kenilworth/NJ/United States of America, 5Netherlands Cancer Institute, Plesmanlaan/ Netherlands; 12 patients had stable disease, resulting in a disease control rate of 76%; median duration of response was 9.2 months; median progression-free survival was 5.8 months, with 6- and 12-month PFS rates of 50% and 25%, respectively
- Median overall survival was 18.0 months with 6- and 12-month OS rates of 83.5% and 62.6%, respectively
- Long-term administration of pembrolizumab is feasible in patients with MPM, and no new safety signals were identified
- KEYNOTE-028 is a nonrandomized, multicohort phase 1b trial of pembrolizumab in patients with PD-L1epositive advanced solid tumors. 25 patients with MPM were treated with pembrolizumab in the mesothelioma cohort
- We examined biopsy specimens from 12 Malignant pleural mesothelioma patients that were removed during maximal cyto-reductive surgery
Need more features? Save interactive summary cards to your Scholarcy Library.